SCHEMBL408247

SCHEMBL408247

CNCCCC(=O)N(C)C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
KDM4A O75164 10/20 0.47
KDM4C Q9H3R0 10/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA4 P43681 1/20 0.47
HTT P42858 1/20 0.39
LMNA P02545 1/20 0.36
PRMT3 O60678 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT1 Q99873 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
KISS1R Q969F8 1/20 0.34
KDM5A P29375 1/20 0.33
KDM7A Q6ZMT4 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
EPHX1 P07099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19914456 0.93 KDM4A (0.55) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL13292130 0.91 KDM4A (0.58) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL2536587 0.85
SCHEMBL31170497 0.83 KDM4A (0.42) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL24850938 0.82 KDM4A (0.44) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL13292131 0.81 DNM1 (0.50) ALDH1A1KDM4AKDM4CHTT
SCHEMBL31170324 0.80 KDM4A (0.43) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL131476 0.79 ALDH1A1 (0.74) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL5948495 0.79 ALDH1A1 (0.74) ALDH1A1KDM4AKDM4CCHRNB2CHRNB4
SCHEMBL14365830 0.79 ALDH1A1 (0.48) ALDH1A1CHRNB2CHRNB4CHRNA4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473295-B2 Substituted straight chain spiro derivatives JANSSEN PHARMACEUTICA NV (BE) 2025-11-18 US disclosed
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
WO-2022087624-A1 COMPOUNDS AS RAS INHIBITORS AND USES THEREOF BIOARDIS LLC (US) 2022-04-28 WO disclosed
WO-2018039621-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. (US) 2018-03-01 WO disclosed
EP-3091011-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2017-12-27 EP disclosed
EP-2964617-B1 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY BOEHRINGER INGELHEIM INT (DE) 2017-04-12 EP disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-7737166-B2 Antifungal bicyclic hetero ring compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-06-15 US disclosed
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1932837-A1 BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION Daiichi Sankyo Company, Limited (JP) 2008-06-18 EP disclosed
EP-0215942-B1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD ANTIVIRALS INC (US) 1995-07-12 EP disclosed
EP-0639582-A2 Polynucleotide assay reagent and method ANTIVIRALS INC. (US) 1995-02-22 EP disclosed
US-5217866-A Polynucleotide assay reagent and method ANTI-GENE DEVELOPMENT GROUP (US) 1993-06-08 US disclosed
EP-0215942-A4 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1988-08-23 EP disclosed
EP-0215942-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1987-04-01 EP disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides CTPS1, TPP1, STS ALDH1A1 835/4885KDM4A 1924/4885KDM4C 1815/4885
US-12473295-B2 Substituted straight chain spiro derivatives MLLT1, MEN1, MLLT3 ALDH1A1 2388/4885KDM4A 1626/4885KDM4C 2512/4885
US-20230142285-A1 SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES MLLT1, MEN1, MLLT3 ALDH1A1 2388/4885KDM4A 1626/4885KDM4C 2512/4885
US-20120065196-A1 AMIDE COMPOUNDS DGAT2, DGAT1, DLAT ALDH1A1 272/4885KDM4A 3166/4885KDM4C 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.